Activity of imipenem-relebactam, ceftolozane-tazobactam and comparators against clinical isolates of Enterobacterales and Pseudomonas aeruginosa causing severe infections in hematological and oncological patients: A prospective multicenter study
TOL/TAZ and IMP/REL were the most active of the beta-lactams against PA. IMP/REL was the most active agent against EB; 30% of the isolates were resistant to levofloxacin.
Authors
- Luís Alcalá
- Belén Rodríguez‐Sánchez (ORCID: https://orcid.org/0000-0002-9625-427X)
- Emilia Cercenado (ORCID: https://orcid.org/0000-0002-5279-3773)
- Mercedes Marín (ORCID: https://orcid.org/0000-0001-8639-5215)
- Álvaro Irigoyen-von-Sierakowski
Institutions
- Hospital General Universitario Gregorio Marañón (ES)
Publication Details
- Journal
- International Journal of Antimicrobial Agents
- Published
- 2025-05-08
- DOI
- https://doi.org/10.1016/j.ijantimicag.2025.107534
- Primary Topic
- Neutropenia and Cancer Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Merck
- Meso Scale Diagnostics